IgG4相关病复发预测因素及血清学不稳定状态:中国大型队列研究
该回顾性研究纳入277例IgG4相关病患者,随访超过4个月,发现36个月累积复发率为36.1%。从诊断到治疗时间较长和过敏史是独立复发危险因素,而对血清学不稳定状态进行干预并未降低复发率。
要点
- 从诊断到治疗时间较长和过敏史是IgG4相关病复发的独立危险因素。
- 12、24、36个月累积复发率分别为12.86%、27.84%和36.1%。
- 对血清IgG4升高的血清学不稳定状态进行干预未降低复发率。
核心结论
- IgG4相关病复发的独立危险因素为从诊断到治疗时间较长和过敏史。
- 对血清学不稳定状态进行干预未有助于降低复发率。
研究设计与样本
- 回顾性研究,纳入北京大学人民医院2012年2月至2019年2月的277例IgG4相关病患者,均随访超过4个月。
- 主要结局为患者复发,记录症状复发、实验室和影像学表现及血清学不稳定状态的治疗信息。
主要发现
- 12、24、36个月累积复发率分别为12.86%、27.84%和36.1%。
- 发病年龄较小、诊断年龄较小、从诊断到治疗时间较长和过敏史与复发相关。
- 从诊断到治疗时间较长和过敏史为独立危险因素。
- 血清IgG4水平较缓解期高20%、50%或100%时,免疫抑制强化组与非强化组最终复发百分比相似。
- 强化组与非强化组从血清IgG4水平不稳定到复发的持续中位时间无统计学差异。
临床怎么用
- 对从诊断到治疗时间较长或有过敏史的IgG4相关病患者应警惕复发风险。
- 血清IgG4水平升高时,强化免疫抑制干预可能不降低复发率,需权衡治疗策略。
局限性
- 为单中心回顾性研究,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Patients with IgG4-related disease (IgG4-RD) typically respond well to initial glucocorticoid therapy, but always relapse with tapered or maintenance dosage of steroid. We aimed to identify the risk factors for relapse of IgG4-RD and explore the impact of active intervention on the serologically unstable condition. METHODS: We performed a retrospective study of 277 IgG4-RD patients at Peking University People's Hospital from February 2012 through February 2019. They were all followed for >4 months. The primary outcome was patient relapse. Data on recurrence of IgG4-RD symptoms, laboratory and image findings were recorded, along with information on treatment in the serologically unstable condition. RESULTS: The cumulative relapse rate was 12.86%, 27.84% and 36.1% at 12, 24 and 36 months, respectively. Younger age at onset, younger age at diagnosis, longer time from diagnosis to treatment and history of allergy were associated with relapse. Identified independent risk factors were longer time from diagnosis to treatment and history of allergy. When serum IgG4 level was 20%, 50% or 100% higher than that of the remission period, similar percentages of patients finally relapsed, regardless of whether they were in the immunosuppression intensified or non-intensified group. Median duration from serum IgG4 level instability to relapse in the intensified and non-intensified group was not statistically different. CONCLUSION: The risk factors of relapse were longer time from diagnosis to treatment and history of allergy. Intervention in the serologically unstable condition was not helpful for reducing relapse rate.
引用
- Liu Y, Zeng Q, Zhu L, et al. Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort. Rheumatology (Oxford). 2020. PMID: 32097488. doi:10.1093/rheumatology/kez669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。